A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of adding Symlin [pramlintide] to Lantus (insulin glargine) in subjects with type 2 diabetes who are not achieving glycemic targets

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of adding Symlin [pramlintide] to Lantus (insulin glargine) in subjects with type 2 diabetes who are not achieving glycemic targets

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2015

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amylin Pharmaceuticals; AstraZeneca
  • Most Recent Events

    • 08 Nov 2006 Status change
    • 27 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top